Abstract P1-03-02: Preclinical efficacy of a novel and potent inhibitor of the MDM2-p53 axis AMG 232 in ER+ breast cancer modelPK De, B Leyland-Jones, JH Carlson et al.|Cancer Research|2018Cited by 0
Abstract 644: Validation of PD-L1 staining by IHC in solid tumors: A journey from xenograft model to ex vivo culture of clinical samplesXiaoqian Lin, Brian Leyland‐Jones, Yuliang Sun et al.|Cancer Research|2018Cited by 0